In the last decade, however, a GnRH antagonist protocol has become preferred for pituitary desensitization worldwide, because it is a more patient friendly approach that also reduces the risk of ovarian hyperstimulation syndrome (OHSS) [5]. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.